{"transactions":[{"id":1051292,"issuer":{"id":7639,"kind":"organization","name":"Neuphoria Therapeutics Inc."},"owners":[{"id":75908,"kind":"person","name":"Papapetropoulos Spyros","position":1,"cik":"0001832694","reported_name":"Papapetropoulos Spyros","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (Right-to- Buy)","published_at":"2025-09-02T11:02:44.000Z","date":"2025-08-27","kind":"grant","planned":false,"acquired":true,"shares":34559,"price":8.27,"value":285802.93,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to the Reporting Person's continuing service with the Company, the options shall vest on a monthly basis over a four-year period at the rate of 2.0833% of the shares of Common Stock on the last day of each month following August 1, 2025 until the options are fully vested."}],"balance_after":74088,"derivative":{"exercise_price":8.27,"expiration_date":"2035-08-27","underlying":"Common Stock","underlying_shares":34559},"source":{"system":"sec-edgar","filing":"0001213900-25-082904","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1191070/000121390025082904/ownership.xml","form_type":"4"}},{"id":1120952,"issuer":{"id":7696,"kind":"organization","name":"Lipocine Inc."},"owners":[{"id":75908,"kind":"person","name":"Papapetropoulos Spyros","position":1,"cik":"0001832694","reported_name":"Papapetropoulos Spyros","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-05T20:06:40.000Z","date":"2025-06-04","kind":"grant","planned":false,"acquired":true,"shares":1764,"price":3.2,"value":5644.8,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% vesting one year from date of grant."}],"balance_after":7174,"derivative":{"exercise_price":3.2,"exercise_date":"2026-06-04","expiration_date":"2035-06-04","underlying":"Common Stock","underlying_shares":1764},"source":{"system":"sec-edgar","filing":"0001641172-25-013797","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1535955/000164117225013797/ownership.xml","form_type":"4"}},{"id":1142286,"issuer":{"id":7639,"kind":"organization","name":"Neuphoria Therapeutics Inc."},"owners":[{"id":75908,"kind":"person","name":"Papapetropoulos Spyros","position":1,"cik":"0001832694","reported_name":"Papapetropoulos Spyros","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (Right-to-Buy)","published_at":"2025-05-19T20:40:14.000Z","date":"2025-04-16","kind":"grant","planned":false,"acquired":true,"shares":27000,"price":5.16,"value":139320.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The original Form 4, filed on April 17, 2025, is amended by this Form 4/A solely to correct a clerical error, which resulted in misreporting the number of derivative securities acquired (Item 5) and amount of securities underlying the derivative securities (Item 7) as 270,000 when the actual number of derivative securities acquired and amount of securities underlying the derivative securities was 27,000. With the correction of the clerical error, the number of derivative securities beneficially owned following the reported transaction (Item 9) is 39,529 shares."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Subject to the Reporting Person's continuing service with the Company, the options shall vest on a monthly basis over a three-year period at the rate of 2.78% of the shares of Common Stock on the last day of each month following September 1, 2024 until the options are vested."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The original Form 4, filed on April 17, 2025, is amended by this Form 4/A solely to correct a clerical error, which resulted in misreporting the number of derivative securities acquired (Item 5) and amount of securities underlying the derivative securities (Item 7) as 270,000 when the actual number of derivative securities acquired and amount of securities underlying the derivative securities was 27,000. With the correction of the clerical error, the number of derivative securities beneficially owned following the reported transaction (Item 9) is 39,529 shares."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The original Form 4, filed on April 17, 2025, is amended by this Form 4/A solely to correct a clerical error, which resulted in misreporting the number of derivative securities acquired (Item 5) and amount of securities underlying the derivative securities (Item 7) as 270,000 when the actual number of derivative securities acquired and amount of securities underlying the derivative securities was 27,000. With the correction of the clerical error, the number of derivative securities beneficially owned following the reported transaction (Item 9) is 39,529 shares."}],"balance_after":39529,"derivative":{"exercise_price":5.16,"expiration_date":"2035-04-16","underlying":"Common Stock","underlying_shares":27000},"source":{"system":"sec-edgar","filing":"0001213900-25-045445","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1191070/000121390025045445/ownership.xml","form_type":"4/A","original_submission_date":"2025-04-17"}},{"id":1169041,"issuer":{"id":7639,"kind":"organization","name":"Neuphoria Therapeutics Inc."},"owners":[{"id":75908,"kind":"person","name":"Papapetropoulos Spyros","position":1,"cik":"0001832694","reported_name":"Papapetropoulos Spyros","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (Right-to-Buy)","published_at":"2025-04-18T12:04:03.000Z","date":"2025-04-16","kind":"grant","planned":false,"acquired":true,"shares":270000,"price":5.16,"value":1393200.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to the Reporting Person's continuing service with the Company, the options shall vest on a monthly basis over a three-year period at the rate of 2.78% of the shares of Common Stock on the last day of each month following September 1, 2024 until the options are vested."}],"balance_after":282529,"derivative":{"exercise_price":5.16,"expiration_date":"2035-04-16","underlying":"Common Stock","underlying_shares":270000},"source":{"system":"sec-edgar","filing":"0001213900-25-033144","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1191070/000121390025033144/ownership.xml","form_type":"4"}},{"id":1486209,"issuer":{"id":7696,"kind":"organization","name":"Lipocine Inc."},"owners":[{"id":75908,"kind":"person","name":"Papapetropoulos Spyros","position":1,"cik":"0001832694","reported_name":"Papapetropoulos Spyros","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-07T21:48:20.000Z","date":"2024-06-05","kind":"grant","planned":false,"acquired":true,"shares":1764,"price":7.05,"value":12436.2,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% vesting one year from date of grant."}],"balance_after":5410,"derivative":{"exercise_price":7.05,"exercise_date":"2025-06-05","expiration_date":"2034-06-05","underlying":"Common Stock","underlying_shares":1764},"source":{"system":"sec-edgar","filing":"0001493152-24-023215","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1535955/000149315224023215/ownership.xml","form_type":"4"}},{"id":1894732,"issuer":{"id":7696,"kind":"organization","name":"Lipocine Inc."},"owners":[{"id":75908,"kind":"person","name":"Papapetropoulos Spyros","position":1,"cik":"0001832694","reported_name":"Papapetropoulos Spyros","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-05-12T20:37:29.000Z","date":"2023-05-10","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0.2656,"value":7968.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% vesting one year from date of grant."}],"balance_after":62000,"derivative":{"exercise_price":0.2656,"exercise_date":"2024-05-10","expiration_date":"2033-05-10","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001493152-23-016695","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1535955/000149315223016695/ownership.xml","form_type":"4"}},{"id":2103173,"issuer":{"id":7696,"kind":"organization","name":"Lipocine Inc."},"owners":[{"id":75908,"kind":"person","name":"Papapetropoulos Spyros","position":1,"cik":"0001832694","reported_name":"Papapetropoulos Spyros","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2022-11-28T21:33:12.000Z","date":"2022-11-22","kind":"purchase","acquired":true,"shares":21739,"price":0.47,"value":10217.33,"ownership":{"direct":true},"balance_after":21739,"source":{"system":"sec-edgar","filing":"0001493152-22-033841","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1535955/000149315222033841/ownership.xml","form_type":"4"}},{"id":2106204,"issuer":{"id":11675,"kind":"organization","name":"Vigil Neuroscience, Inc.","symbol":"VIGL"},"owners":[{"id":75908,"kind":"person","name":"Papapetropoulos Spyros","position":1,"cik":"0001832694","reported_name":"Papapetropoulos Spyros","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option Grant (Right to Buy)","published_at":"2022-11-22T21:45:28.000Z","date":"2022-11-18","kind":"exercise","acquired":false,"shares":300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares subject to this option vested and became exercisable on September 14, 2021, with the remainder vesting in 36 equal monthly installments thereafter."}],"balance_after":149604,"derivative":{"exercise_price":1.89,"expiration_date":"2030-11-18","underlying":"Common Stock","underlying_shares":300},"source":{"system":"sec-edgar","filing":"0000899243-22-036831","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1827087/000089924322036831/doc4.xml","form_type":"4"}},{"id":2106203,"issuer":{"id":11675,"kind":"organization","name":"Vigil Neuroscience, Inc.","symbol":"VIGL"},"owners":[{"id":75908,"kind":"person","name":"Papapetropoulos Spyros","position":1,"cik":"0001832694","reported_name":"Papapetropoulos Spyros","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-11-22T21:45:28.000Z","date":"2022-11-18","kind":"sale","acquired":false,"shares":300,"price":14,"value":4200.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 13, 2022."}],"balance_after":4000,"source":{"system":"sec-edgar","filing":"0000899243-22-036831","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1827087/000089924322036831/doc4.xml","form_type":"4"}},{"id":2106202,"issuer":{"id":11675,"kind":"organization","name":"Vigil Neuroscience, Inc.","symbol":"VIGL"},"owners":[{"id":75908,"kind":"person","name":"Papapetropoulos Spyros","position":1,"cik":"0001832694","reported_name":"Papapetropoulos Spyros","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-11-22T21:45:28.000Z","date":"2022-11-18","kind":"exercise","acquired":true,"shares":300,"price":1.89,"value":567.0,"ownership":{"direct":true},"balance_after":4300,"source":{"system":"sec-edgar","filing":"0000899243-22-036831","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1827087/000089924322036831/doc4.xml","form_type":"4"}},{"id":2235475,"issuer":{"id":7696,"kind":"organization","name":"Lipocine Inc."},"owners":[{"id":75908,"kind":"person","name":"Papapetropoulos Spyros","position":1,"cik":"0001832694","reported_name":"Papapetropoulos Spyros","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-10T15:34:11.000Z","date":"2022-06-08","kind":"grant","acquired":true,"shares":22000,"price":0.92,"value":20240.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to vesting whereby all of the shares subject to the award will vest on the one year anniversary of June 8, 2023."}],"balance_after":32000,"derivative":{"exercise_price":0.92,"exercise_date":"2023-06-08","expiration_date":"2032-06-08","underlying":"Common Stock","underlying_shares":22000},"source":{"system":"sec-edgar","filing":"0001493152-22-016402","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1535955/000149315222016402/ownership.xml","form_type":"4"}},{"id":2281665,"issuer":{"id":11675,"kind":"organization","name":"Vigil Neuroscience, Inc.","symbol":"VIGL"},"owners":[{"id":75908,"kind":"person","name":"Papapetropoulos Spyros","position":1,"cik":"0001832694","reported_name":"Papapetropoulos Spyros","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-05-04T07:00:11.000Z","date":"2022-05-03","kind":"purchase","acquired":true,"shares":4000,"price":3.3978,"value":13591.2,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $3.276 to $3.4059, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected."}],"balance_after":4000,"source":{"system":"sec-edgar","filing":"0000899243-22-016530","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1827087/000089924322016530/doc4.xml","form_type":"4"}},{"id":2298227,"issuer":{"id":7696,"kind":"organization","name":"Lipocine Inc."},"owners":[{"id":75908,"kind":"person","name":"Papapetropoulos Spyros","position":1,"cik":"0001832694","reported_name":"Papapetropoulos Spyros","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-04-12T21:00:09.000Z","date":"2022-04-11","kind":"grant","acquired":true,"shares":10000,"price":1.16,"value":11600.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to vesting whereby 1/3 of the shares subject to the award will vest on the one year anniversary of April 11, 2023, while the remaining 2/3 of the shares subject to the award will vest monthly on a prorate basis over the following two years."}],"balance_after":10000,"derivative":{"exercise_price":1.16,"exercise_date":"2023-04-11","expiration_date":"2032-04-11","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001493152-22-009718","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1535955/000149315222009718/ownership.xml","form_type":"4"}},{"id":2352339,"issuer":{"id":11675,"kind":"organization","name":"Vigil Neuroscience, Inc.","symbol":"VIGL"},"owners":[{"id":75908,"kind":"person","name":"Papapetropoulos Spyros","position":1,"cik":"0001832694","reported_name":"Papapetropoulos Spyridon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option Grant (Right to Buy)","published_at":"2022-03-03T16:05:54.000Z","date":"2022-03-01","kind":"grant","acquired":true,"shares":75500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable in forty-eight (48) equal monthly installments, with the first installment vesting on April 1, 2022."}],"balance_after":75500,"derivative":{"exercise_price":16.13,"expiration_date":"2032-03-01","underlying":"Common Stock","underlying_shares":75500},"source":{"system":"sec-edgar","filing":"0000899243-22-009052","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1827087/000089924322009052/doc4.xml","form_type":"4"}},{"id":2494921,"issuer":{"id":133085,"kind":"organization","name":"Adamas Pharmaceuticals Inc","symbol":"ADMS"},"owners":[{"id":75908,"kind":"person","name":"Papapetropoulos Spyros","position":1,"cik":"0001832694","reported_name":"Papapetropoulos Spyridon","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-11-24T16:09:09.000Z","date":"2021-11-24","kind":"disposition_to_issuer","acquired":false,"shares":10000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"$2.89 plus two CVRs per share underlying the stock option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and with a per share exercise price less than $8.10, was cancelled at the Effective Time and automatically converted into the right to receive for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, two CVRs plus the excess of (i) $8.10 over (ii) the per share exercise price of such Issuer option."}],"balance_after":0,"derivative":{"exercise_price":5.21,"exercise_date":"2022-06-02","expiration_date":"2031-06-01","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001328143-21-000089","document":"wf-form4_163778813188822.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1328143/000132814321000089/wf-form4_163778813188822.xml","form_type":"4"}},{"id":2494920,"issuer":{"id":133085,"kind":"organization","name":"Adamas Pharmaceuticals Inc","symbol":"ADMS"},"owners":[{"id":75908,"kind":"person","name":"Papapetropoulos Spyros","position":1,"cik":"0001832694","reported_name":"Papapetropoulos Spyridon","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-11-24T16:09:09.000Z","date":"2021-11-24","kind":"disposition_to_issuer","acquired":false,"shares":20000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"$3.75 plus two CVRs per share underlying the stock option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares subject to the option vest annually in equal installments over 3 years."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and with a per share exercise price less than $8.10, was cancelled at the Effective Time and automatically converted into the right to receive for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, two CVRs plus the excess of (i) $8.10 over (ii) the per share exercise price of such Issuer option."}],"balance_after":0,"derivative":{"exercise_price":4.35,"expiration_date":"2030-11-21","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001328143-21-000089","document":"wf-form4_163778813188822.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1328143/000132814321000089/wf-form4_163778813188822.xml","form_type":"4"}},{"id":2494919,"issuer":{"id":133085,"kind":"organization","name":"Adamas Pharmaceuticals Inc","symbol":"ADMS"},"owners":[{"id":75908,"kind":"person","name":"Papapetropoulos Spyros","position":1,"cik":"0001832694","reported_name":"Papapetropoulos Spyridon","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-11-24T16:09:09.000Z","date":"2021-11-24","kind":"other","acquired":false,"shares":20975,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of October 10, 2021, by and among the Issuer, Supernus Pharmaceuticals, Inc. (\"Parent\") and Supernus Reef, Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer (the \"Merger\") effective as of November 24, 2021 (the \"Effective Time\"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $8.10 in cash plus two contingent value rights (\"CVRs\" and, collectively with the cash amount, the \"Per Share Price\")."},{"field":"shares","element":"transactionShares","label":"F2","text":"A portion of this amount consists of unvested restricted stock units (\"RSUs\"). Pursuant to the terms of the Merger Agreement, each Issuer RSU that was outstanding immediately prior to the Effective Time was cancelled at the Effective Time and automatically converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding under applicable tax law, the Per Share Price."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Disposed of pursuant to Merger Agreement in exchange for $8.10 plus two CVRs per share. The CVRs do not have a market value."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001328143-21-000089","document":"wf-form4_163778813188822.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1328143/000132814321000089/wf-form4_163778813188822.xml","form_type":"4"}},{"id":2680584,"issuer":{"id":133085,"kind":"organization","name":"Adamas Pharmaceuticals Inc","symbol":"ADMS"},"owners":[{"id":75908,"kind":"person","name":"Papapetropoulos Spyros","position":1,"cik":"0001832694","reported_name":"Papapetropoulos Spyridon","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-04T16:16:19.000Z","date":"2021-06-02","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Option shares vest in full on the one year anniversary of the grant date, subject to Reporting Person's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) as of such date."}],"balance_after":10000,"derivative":{"exercise_price":5.21,"exercise_date":"2022-06-02","expiration_date":"2031-06-01","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001328143-21-000060","document":"wf-form4_162283774705681.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1328143/000132814321000060/wf-form4_162283774705681.xml","form_type":"4"}},{"id":2680583,"issuer":{"id":133085,"kind":"organization","name":"Adamas Pharmaceuticals Inc","symbol":"ADMS"},"owners":[{"id":75908,"kind":"person","name":"Papapetropoulos Spyros","position":1,"cik":"0001832694","reported_name":"Papapetropoulos Spyridon","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-04T16:16:19.000Z","date":"2021-06-02","kind":"grant","acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares of Common Stock are to be acquired upon the vesting of certain Restricted Stock Units granted to the Reporting Person. The Restricted Stock Units shall vest on the one year anniversary of the grant date, subject to Reporting Person's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) as of such date."}],"balance_after":20975,"source":{"system":"sec-edgar","filing":"0001328143-21-000060","document":"wf-form4_162283774705681.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1328143/000132814321000060/wf-form4_162283774705681.xml","form_type":"4"}},{"id":2788914,"issuer":{"id":133085,"kind":"organization","name":"Adamas Pharmaceuticals Inc","symbol":"ADMS"},"owners":[{"id":75908,"kind":"person","name":"Papapetropoulos Spyros","position":1,"cik":"0001832694","reported_name":"Papapetropoulos Spyridon","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-03-15T15:24:53.000Z","date":"2021-03-11","kind":"purchase","acquired":true,"shares":5975,"price":5.06,"value":30233.5,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares were purchased at prices ranging from $4.85 to $5.15. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares purchased at each separate price."}],"balance_after":15975,"source":{"system":"sec-edgar","filing":"0001209191-21-020418","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1328143/000120919121020418/doc4.xml","form_type":"4"}},{"id":2967713,"issuer":{"id":133085,"kind":"organization","name":"Adamas Pharmaceuticals Inc","symbol":"ADMS"},"owners":[{"id":75908,"kind":"person","name":"Papapetropoulos Spyros","position":1,"cik":"0001832694","reported_name":"Papapetropoulos Spyridon","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Rightto Buy)","published_at":"2020-11-24T17:57:03.000Z","date":"2020-11-22","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option vest annually in equal installments over 3 years."}],"balance_after":20000,"derivative":{"exercise_price":4.35,"expiration_date":"2030-11-21","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-20-060298","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1328143/000120919120060298/doc4.xml","form_type":"4"}},{"id":2967712,"issuer":{"id":133085,"kind":"organization","name":"Adamas Pharmaceuticals Inc","symbol":"ADMS"},"owners":[{"id":75908,"kind":"person","name":"Papapetropoulos Spyros","position":1,"cik":"0001832694","reported_name":"Papapetropoulos Spyridon","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-11-24T17:57:03.000Z","date":"2020-11-22","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the grant of restricted stock units that vest annually in equal installments over 3 years."}],"balance_after":10000,"source":{"system":"sec-edgar","filing":"0001209191-20-060298","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1328143/000120919120060298/doc4.xml","form_type":"4"}}]}